EIM
PACB icon

Essex Investment Management’s Pacific Biosciences PACB Stock Holding History

Essex Investment Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-6,059
Closed -$59.4K – 328
2023
Q4 		$59.4K Sell
6,059
-4,301
-42% -$35.2K 0.01% 258
2023
Q3 		$86.5K Sell
10,360
-99
-0.9% -$1.13K 0.01% 301
2023
Q2 		$139K Hold
10,459
– – 0.02% 290
2023
Q1 		$121K Buy
10,459
+4,601
+79% +$45.7K 0.02% 296
2022
Q4 		$48K Hold
5,858
– – 0.01% 318
2022
Q3 		$34K Hold
5,858
– – 0.01% 325
2022
Q2 		$26K Sell
5,858
-4,549
-44% -$27.6K ﹤0.01% 346
2022
Q1 		$95K Buy
10,407
+1,349
+15% +$15.5K 0.01% 319
2021
Q4 		$185K Buy
9,058
+1,225
+16% +$29.6K 0.02% 313
2021
Q3 		$200K Hold
7,833
– – 0.02% 322
2021
Q2 		$274K Buy
+7,833
New +$228K 0.03% 312
2017
Q3 		– Sell
-253,158
Closed -$901K – 375
2017
Q2 		$901K Buy
253,158
+102,640
+68% +$414K 0.13% 206
2017
Q1 		$778K Buy
150,518
+75,837
+102% +$371K 0.12% 219
2016
Q4 		$284K Buy
74,681
+28,857
+63% +$210K 0.05% 299
2016
Q3 		$411K Sell
45,824
-1,075
-2% -$8.99K 0.07% 271
2016
Q2 		$330K Sell
46,899
-517
-1% -$4.72K 0.05% 273
2016
Q1 		$403K Sell
47,416
-32,120
-40% -$316K 0.07% 256
2015
Q4 		$1.04M Sell
79,536
-73,939
-48% -$663K 0.16% 145
2015
Q3 		$562K Buy
153,475
+6,423
+4% +$31.4K 0.09% 217
2015
Q2 		$847K Sell
147,052
-3,092
-2% -$17.9K 0.13% 178
2015
Q1 		$877K Sell
150,144
-1,109
-0.7% -$7.65K 0.12% 171
2014
Q4 		$1.19M Sell
151,253
-23,949
-14% -$153K 0.17% 136
2014
Q3 		$860K Sell
175,202
-11,289
-6% -$59K 0.13% 177
2014
Q2 		$1.15M Buy
+186,491
New +$933K 0.17% 164
2014
Q1 		– Sell
-197,310
Closed -$1.03M – 366
2013
Q4 		$1.03M Buy
+197,310
New +$906K 0.15% 189

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Essex Investment Management's PACB Position: Q1 2024 in Review

Essex Investment Management sold out of Pacific Biosciences (PACB) in Q1 2024, closing a stake of 6,059 shares — an estimated $59.4K sold.

Essex Investment Management first reported a position in PACB in Q4 2013 and held it in 25 quarters. The position peaked at $1.19M in Q4 2014. 268 funds tracked by Wall St. Rank hold PACB as of Q1 2024.

  • Essex Investment Management reported no remaining Pacific Biosciences position as of Q1 2024 after selling out during the quarter.
  • Essex Investment Management sold 6,059 Pacific Biosciences shares in Q1 2024, an estimated $59.4K.
  • Essex Investment Management first reported a position in Pacific Biosciences in Q4 2013 and held it in 25 quarters.
  • Essex Investment Management's Pacific Biosciences position peaked at $1.19M in Q4 2014.
  • 268 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2024.

Based on Essex Investment Management's 13F filing for Q1 2024, filed 3 May 2024.